Expert Insights On Downstream Bioprocessing
-
How Do We Best Meet Future AAV Production Challenges?
12/20/2024
In the recent past, viral vector manufacturers feared a capacity crunch. Now, with vastly improved productivity, predicting demand is a challenge.
-
AP Biosciences' Approach To Complex Antibody Manufacturing
12/19/2024
The bispecific developer's vice president of antibody discovery, Jhong-Jhe You, digs into the company's approach to purification and analytics.
-
USP Chapter Covers Residual DNA Testing Practices For CHO And E. coli
12/3/2024
Industry widely uses qPCR to measure residual DNA; however, the technique lacked a standard. USP's General Chapter <509> aims to remedy that.
-
Research Explores Alternative To EU-Banned Triton X-100
11/20/2024
One of the best-known viral inactivation agents is now banned in the EU. A group of scientists explored Virodex TXR-1 as a suitable alternative. Here's what they found.
-
A Risk-Based Approach To Filter Integrity Testing Annex 1 Requirements For Biologics DS
11/8/2024
How do the principles of filter integrity testing described in EudraLex Annex 1 apply to low bioburden drug substance manufacturing? And how can using a risk-based approach help?
-
Aligning Sterile Filtration With EU GMP Guide Annex 1 Standards
10/28/2024
A recent chapter by GMP Compliance Adviser explores sterile filtration including filter qualification, process validation, and integrity testing through an Annex 1 lens.
-
Survey Says Downstream Biomanufacturing Bottleneck Is Over
10/11/2024
BioPlan's 21st annual survey finds that downstream processing capacity constraints are at their lowest reported in years.
-
Upping Flow Of Advanced Technologies Into Commercial Biomanufacturing
9/12/2024
A set of tools NASA developed assessing new, rapidly developed and deployed technology could help biopharmas adopt advanced tech post-commercialization.
-
FDA Issues Revised Guidance On Controlling Nitrosamine Impurities In Pharmaceuticals
9/11/2024
The FDA has issued a revised version of its guidance, Control of Nitrosamine Impurities in Human Drugs. This article explores the agency's recommendations, root causes of nitrosamines, and strategies for mitigating their presence in pharmaceuticals.
-
Capacity, AI Driving Single-use Bioprocess Probe And Sensor Uptake
8/30/2024
Disposable probes and sensors offer advantages over their reusable counterparts, especially as industry moves toward flexible, scalable production models.